Towards the rational design of antimicrobial proteins: Single point mutations can switch on bactericidal and agglutinating activities on the RNase A superfamily lineage

FEBS Journal

Volumn 280, Issue 22, 2013, Pages 5841-5852

  Pulido, David ^a   Moussaoui, Mohammed ^a   Victoria Nogues M ^a   Torrent, Marc ^a,b   Boix, Ester ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

antimicrobial peptides; eosinophil cationic protein; eosinophil derived neurotoxin; protein evolution; ribonuclease

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL PROTEIN X; POLYPEPTIDE ANTIBIOTIC AGENT; RIBONUCLEASE A;

ARTICLE; BACTERIAL OUTER MEMBRANE; BACTERICIDAL ACTIVITY; BINDING AFFINITY; CELL AGGLUTINATION; CONTROLLED STUDY; GRAM NEGATIVE BACTERIUM; HUMAN; HUMAN CELL; MEMBRANE BINDING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ENGINEERING;

ANTIMICROBIAL PEPTIDES; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL-DERIVED NEUROTOXIN; PROTEIN EVOLUTION; RIBONUCLEASE;

AGGLUTININS; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ENDORIBONUCLEASES; EOSINOPHIL CATIONIC PROTEIN; GRAM-NEGATIVE BACTERIA; HUMANS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; POINT MUTATION; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; RIBONUCLEASE, PANCREATIC;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; PRIMATES;

EID: 84886597087     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12506     Document Type: Article

References (67)

1. Beintema JJ, &, Kleineidam RG, (1998) The ribonuclease A superfamily: general discussion. Cell Mol Life Sci 54, 825-832.
2. Cuchillo CM, Nogues MV, &, Raines RT, (2011) Bovine pancreatic ribonuclease: fifty years of the first enzymatic reaction mechanism. Biochemistry 50, 7835-7841.
3. Sorrentino S, (2010) The eight human 'canonical' ribonucleases: molecular diversity, catalytic properties, and special biological actions of the enzyme proteins. FEBS Lett 584, 2194-2200.
4. Raines RT, (1998) Ribonuclease A. Chem Rev 98, 1045-1066.
5. Boix E, &, Nogues MV, (2007) Mammalian antimicrobial proteins and peptides: overview on the RNase A superfamily members involved in innate host defence. Mol BioSyst 3, 317-335.
6. Cho S, &, Zhang J, (2007) Zebrafish ribonucleases are bactericidal: implications for the origin of the vertebrate RNase A superfamily. Mol Biol Evol 24, 1259-1268.
7. Pizzo E, &, D'Alessio G, (2007) The success of the RNase scaffold in the advance of biosciences and in evolution. Gene 406, 8-12.
8. Rosenberg HF, (2008) RNase A ribonucleases and host defense: an evolving story. J Leukoc Biol 83, 1079-1087.
9. Boix E, Torrent M, Sanchez D, &, Nogues MV, (2008) The antipathogen activities of eosinophil cationic protein. Curr Pharm Biotechnol 9, 141-152.
10. Malik A, &, Batra JK, (2012) Antimicrobial activity of human eosinophil granule proteins: involvement in host defence against pathogens. Crit Rev Microbiol 38, 168-181.
11. Yousefi S, Simon D, &, Simon HU, (2012) Eosinophil extracellular DNA traps: molecular mechanisms and potential roles in disease. Curr Opin Immunol 24, 736-739.
12. Goldmann O, &, Medina E, (2013) The expanding world of extracellular traps: not only neutrophils but much more. Front Immunol 3, 420.
13. Rosenberg HF, Dyer KD, Tiffany HL, &, Gonzalez M, (1995) Rapid evolution of a unique family of primate ribonuclease genes. Nat Genet 10, 219-223.
14. Zhang J, Rosenberg HF, &, Nei M, (1998) Positive Darwinian selection after gene duplication in primate ribonuclease genes. Proc Natl Acad Sci USA 95, 3708-3713.
15. Hamann KJ, Ten RM, Loegering DA, Jenkins RB, Heise MT, Schad CR, Pease LR, Gleich GJ, &, Barker RL, (1990) Structure and chromosome localization of the human eosinophil-derived neurotoxin and eosinophil cationic protein genes: evidence for intronless coding sequences in the ribonuclease gene superfamily. Genomics 7, 535-546.
16. Zhang J, &, Rosenberg HF, (2002) Complementary advantageous substitutions in the evolution of an antiviral RNase of higher primates. Proc Natl Acad Sci USA 99, 5486-5491.
17. Dyer KD, &, Rosenberg HF, (2006) The RNase a superfamily: generation of diversity and innate host defense. Mol Divers 10, 585-597.
18. Boix E, Salazar VA, Torrent M, Pulido D, Nogues MV, &, Moussaoui M, (2012) Structural determinants of the eosinophil cationic protein antimicrobial activity. Biol Chem 393, 801-815.
19. Singh A, &, Batra JK, (2011) Role of unique basic residues in cytotoxic, antibacterial and antiparasitic activities of human eosinophil cationic protein. Biol Chem 392, 337-346.
20. Durack DT, Ackerman SJ, Loegering DA, &, Gleich GJ, (1981) Purification of human eosinophil-derived neurotoxin. Proc Natl Acad Sci USA 78, 5165-5169.
21. Domachowske JB, Dyer KD, Bonville CA, &, Rosenberg HF, (1998) Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis 177, 1458-1464.
22. Garofalo R, Kimpen JL, Welliver RC, &, Ogra PL, (1992) Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J Pediatr 120, 28-32.
23. Harrison AM, Bonville CA, Rosenberg HF, &, Domachowske JB, (1999) Respiratory syncytical virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. Am J Respir Crit Care Med 159, 1918-1924.
24. Sikriwal D, Seth D, Parveen S, Malik A, Broor S, &, Batra JK, (2012) An insertion in loop L7 of human eosinophil-derived neurotoxin is crucial for its antiviral activity. J Cell Biochem 113, 3104-3112.
25. Lehrer RI, Szklarek D, Barton A, Ganz T, Hamann KJ, &, Gleich GJ, (1989) Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol 142, 4428-4434.
26. Rosenberg HF, (1995) Recombinant human eosinophil cationic protein. Ribonuclease activity is not essential for cytotoxicity. J Biol Chem 270, 7876-7881.
27. Hamann KJ, Gleich GJ, Checkel JL, Loegering DA, McCall JW, &, Barker RL, (1990) In vitro killing of microfilariae of Brugia pahangi and Brugia malayi by eosinophil granule proteins. J Immunol 144, 3166-3173.
28. Yang D, Rosenberg HF, Chen Q, Dyer KD, Kurosaka K, &, Oppenheim JJ, (2003) Eosinophil-derived neurotoxin (EDN), an antimicrobial protein with chemotactic activities for dendritic cells. Blood 102, 3396-3403.
29. Rosenberg HF, (2008) Eosinophil-derived neurotoxin/RNase 2: connecting the past, the present and the future. Curr Pharm Biotechnol 9, 135-140.
30. Yang D, Chen Q, Rosenberg HF, Rybak SM, Newton DL, Wang ZY, Fu Q, Tchernev VT, Wang M, Schweitzer B, et al,. (2004) Human ribonuclease A superfamily members, eosinophil-derived neurotoxin and pancreatic ribonuclease, induce dendritic cell maturation and activation. J Immunol 173, 6134-6142.
31. Yang D, Chen Q, Su SB, Zhang P, Kurosaka K, Caspi RR, Michalek SM, Rosenberg HF, Zhang N, &, Oppenheim JJ, (2008) Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J Exp Med 205, 79-90.
32. Oppenheim JJ, Tewary P, de la Rosa G, &, Yang D, (2007) Alarmins initiate host defense. Adv Exp Med Biol 601, 185-194.
33. Venge P, Bystrom J, Carlson M, Hakansson L, Karawacjzyk M, Peterson C, Seveus L, &, Trulson A, (1999) Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy 29, 1172-1186.
34. Bystrom J, Amin K, &, Bishop-Bailey D, (2011) Analysing the eosinophil cationic protein-a clue to the function of the eosinophil granulocyte. Respir Res 12, 10.
35. Carreras E, Boix E, Rosenberg HF, Cuchillo CM, &, Nogues MV, (2003) Both aromatic and cationic residues contribute to the membrane-lytic and bactericidal activity of eosinophil cationic protein. Biochemistry 42, 6636-6644.
36. McLaren DJ, Peterson CG, &, Venge P, (1984) Schistosoma mansoni: further studies of the interaction between schistosomula and granulocyte-derived cationic proteins in vitro. Parasitology 88, 491-503.
37. Elshafie AI, Hlin E, Hakansson LD, Elghazali G, Safi SH, Ronnelid J, &, Venge P, (2011) Activity and turnover of eosinophil and neutrophil granulocytes are altered in visceral leishmaniasis. Int J Parasitol 41, 463-469.
38. Kierszenbaum F, Villalta F, &, Tai PC, (1986) Role of inflammatory cells in Chagas' disease. III. Kinetics of human eosinophil activation upon interaction with parasites (Trypanosoma cruzi). J Immunol 136, 662-666.
39. Waters LS, Taverne J, Tai PC, Spry CJ, Targett GA, &, Playfair JH, (1987) Killing of Plasmodium falciparum by eosinophil secretory products. Infect Immun 55, 877-881.
40. Pulido D, Torrent M, Andreu D, Nogués MV, &, Boix E, (2013) Two human host defense ribonucleases against mycobacteria, the eosinophil cationic protein (RNase 3) and RNase 7. Antimicrob Agents Chemother 57, 3797-3805.
41. Torrent M, de la Torre BG, Nogues VM, Andreu D, &, Boix E, (2009) Bactericidal and membrane disruption activities of the eosinophil cationic protein are largely retained in an N-terminal fragment. Biochem J 421, 425-434.
42. Torrent M, Pulido D, de la Torre BG, Garcia-Mayoral MF, Nogues MV, Bruix M, Andreu D, &, Boix E, (2011) Refining the eosinophil cationic protein antibacterial pharmacophore by rational structure minimization. J Med Chem 54, 5237-5244.
43. Carreras E, Boix E, Navarro S, Rosenberg HF, Cuchillo CM, &, Nogues MV, (2005) Surface-exposed amino acids of eosinophil cationic protein play a critical role in the inhibition of mammalian cell proliferation. Mol Cell Biochem 272, 1-7.
44. Torrent M, Odorizzi F, Nogues MV, &, Boix E, (2010) Eosinophil cationic protein aggregation: identification of an N-terminus amyloid prone region. Biomacromolecules 11, 1983-1990.
45. Torrent M, Pulido D, Nogues MV, &, Boix E, (2012) Exploring new biological functions of amyloids: bacteria cell agglutination mediated by host protein aggregation. PLoS Pathog 8, e1003005.
46. Torrent M, Navarro S, Moussaoui M, Nogues MV, &, Boix E, (2008) Eosinophil cationic protein high-affinity binding to bacteria-wall lipopolysaccharides and peptidoglycans. Biochemistry 47, 3544-3555.
47. Navarro S, Boix E, Cuchillo CM, &, Nogues MV, (2010) Eosinophil-induced neurotoxicity: the role of eosinophil cationic protein/RNase 3. J Neuroimmunol 227, 60-70.
48. Young JD, Peterson CG, Venge P, &, Cohn ZA, (1986) Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature 321, 613-616.
49. Pulido D, Moussaoui M, Andreu D, Nogues MV, Torrent M, &, Boix E, (2012) Antimicrobial action and cell agglutination by the eosinophil cationic protein are modulated by the cell wall lipopolysaccharide structure. Antimicrob Agents Chemother 56, 2378-2385.
50. Torrent M, Cuyas E, Carreras E, Navarro S, Lopez O, de la Maza A, Nogues MV, Reshetnyak YK, &, Boix E, (2007) Topography studies on the membrane interaction mechanism of the eosinophil cationic protein. Biochemistry 46, 720-733.
51. Collaborative Computational Project, Number 4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50, 760-763.
52. Rosenberg HF, (1998) The eosinophil ribonucleases. Cell Mol Life Sci 54, 795-803.
53. Fan TC, Fang SL, Hwang CS, Hsu CY, Lu XA, Hung SC, Lin SC, &, Chang MD, (2008) Characterization of molecular interactions between eosinophil cationic protein and heparin. J Biol Chem 283, 25468-25474.
54. Lien PC, Kuo PH, Chen CJ, Chang HH, Fang SL, Wu WS, Lai YK, Pai TW, &, Chang MD, (2013) In silico prediction and in vitro characterization of multifunctional human RNase3. Biomed Res Int 2013, 170398.
55. Wimley WC, (2010) Describing the mechanism of antimicrobial peptide action with the interfacial activity model. ACS Chem Biol 5, 905-917.
56. De Samblanx GW, Goderis IJ, Thevissen K, Raemaekers R, Fant F, Borremans F, Acland DP, Osborn RW, Patel S, &, Broekaert WF, (1997) Mutational analysis of a plant defensin from radish (Raphanus sativus L.) reveals two adjacent sites important for antifungal activity. J Biol Chem 272, 1171-1179.
57. Mukherjee S, Partch CL, Lehotzky RE, Whitham CV, Chu H, Bevins CL, Gardner KH, &, Hooper LV, (2009) Regulation of C-type lectin antimicrobial activity by a flexible N-terminal prosegment. J Biol Chem 284, 4881-4888.
58. Torrent M, Valle J, Nogués MV, Boix E, &, Andreu D, (2011) The generation of antimicrobial peptide activity: a trade-off between charge and aggregation? Angew Chem Int Ed Engl 50, 10686-10689.
59. Torrent M, Andreu D, Nogués VM, &, Boix E, (2011) Connecting peptide physicochemical and antimicrobial properties by a rational prediction model. PLoS One 6, e16968. doi: 10.1371/journal.pone.0016968
60. Motizuki M, Itoh T, Yamada M, Shimamura S, &, Tsurugi K, (1998) Purification, primary structure, and antimicrobial activities of bovine apolipoprotein A-II. J Biochem 123, 675-679.
61. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, et al,. (2010) The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 5, e9505.
62. Boix E, Nikolovski Z, Moiseyev GP, Rosenberg HF, Cuchillo CM, &, Nogues MV, (1999) Kinetic and product distribution analysis of human eosinophil cationic protein indicates a subsite arrangement that favors exonuclease-type activity. J Biol Chem 274, 15605-15614.
63. Boix E, Wu Y, Vasandani VM, Saxena SK, Ardelt W, Ladner J, &, Youle RJ, (1996) Role of the N-terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity. J Mol Biol 257, 992-1007.
64. Torrent M, Badia M, Moussaoui M, Sanchez D, Nogues MV, &, Boix E, (2010) Comparison of human RNase 3 and RNase 7 bactericidal action at the Gram-negative and Gram-positive bacterial cell wall. FEBS J 277, 1713-1725.
65. Wood SJ, Miller KA, &, David SA, (2004) Anti-endotoxin agents. 1. Development of a fluorescent probe displacement method optimized for the rapid identification of lipopolysaccharide-binding agents. Comb Chem High Throughput Screen 7, 239-249.
66. Boix E, Leonidas DD, Nikolovski Z, Nogues MV, Cuchillo CM, &, Acharya KR, (1999) Crystal structure of eosinophil cationic protein at 2.4 Å resolution. Biochemistry 38, 16794-16801.
67. Swaminathan GJ, Holloway DE, Veluraja K, &, Acharya KR, (2002) Atomic resolution (0.98 Å) structure of eosinophil-derived neurotoxin. Biochemistry 41, 3341-3352.